Tucatinib is the third approved HER2 kinase inhibitor (after lapatinib and neratinib), but differentiates itself due to its selectivity against the closely related EGFR, which is hypothesized to be a source of undesired side effects with prior inhibitors. Impressively, it’s also demonstrated activity in HER2+ breast cancers with brain [...]